Heart failure & cardiomyopathies
Prognosis of patients in end-stage heart failure with atrial fibrillation treated with ablation: Insights from CASTLE-HTx
Primary result · Primary end point by risk group, ablation vs medical therapyResult — go to the resultHazard ratio 4.98 95% CI 2.08–11.9Authors' conclusion
The absolute benefit of ablation is more pronounced in high-risk patients, but low-risk patients may also benefit.
Study context
- Population
- Patients with end-stage heart failure (HF) and atrial fibrillation (AF)
- Participants
- 194 patients
- Comparison
- AF ablation vs medical therapy, by CASTLE-HTx risk score
- Low riskn = 89reference
- High riskn = 105
- Primary endpoint
- Primary end point (components not defined in abstract)
- Follow-up
- Median 18 months
Primary result
As reported in the abstract
Primary end point by risk group, ablation vs medical therapy
Hazard ratio
4.98
95% CI 2.08–11.9
Events by treatment group
High-risk
31
events
Low-risk
6
events
High-riskvs Low-risk
HR 4.98 (95% CI 2.08–11.9)
Original publication
Prognosis of patients in end-stage heart failure with atrial fibrillation treated with ablation: Insights from CASTLE-HTx. Heart Rhythm. Published 9 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →